Literature DB >> 17449718

The activin A-follistatin system: potent regulator of human extracellular matrix mineralization.

Marco Eijken1, Sigrid Swagemakers, Marijke Koedam, Cobie Steenbergen, Pieter Derkx, André G Uitterlinden, Peter J van der Spek, Jenny A Visser, Frank H de Jong, Huibert A P Pols, Johannes P T M van Leeuwen.   

Abstract

Bone quality is an important determinant of osteoporosis, and proper osteoblast differentiation plays an important role in the control and maintenance of bone quality. We investigated the impact of activin signaling on human osteoblast differentiation, extracellular matrix formation, and mineralization. Activins belong to the transforming growth factor-beta superfamily and activin A treatment strongly inhibited mineralization in osteoblast cultures, whereas the activin antagonist follistatin increased mineralization. Osteoblasts produced activin A and follistatin in a differentiation-dependent manner, leading to autocrine regulation of extracellular matrix formation and mineralization. In addition, mineralization in a vascular smooth muscle cell-based model for pathological calcification was inhibited. Comparative activin A and follistatin gene expression profiling showed that activin signaling changes the expression of a specific range of extracellular matrix proteins prior to the onset of mineralization, leading to a matrix composition with reduced or no mineralizing capacity. These findings demonstrate the regulation of osteoblast differentiation and matrix mineralization by the activin A-follistatin system, providing the possibility to control bone quality as well as pathological calcifications such as atherosclerosis by using activin A, follistatin, or analogs thereof.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17449718     DOI: 10.1096/fj.07-8080com

Source DB:  PubMed          Journal:  FASEB J        ISSN: 0892-6638            Impact factor:   5.191


  70 in total

1.  The influence of follistatin on mechanical properties of bone tissue in growing mice with overexpression of follistatin.

Authors:  Anna Gajos-Michniewicz; Elzbieta Pawlowska; Tomasz Ochedalski; Agnieszka Piastowska-Ciesielska
Journal:  J Bone Miner Metab       Date:  2012-02-07       Impact factor: 2.626

Review 2.  Signaling pathways affecting skeletal health.

Authors:  Pierre J Marie
Journal:  Curr Osteoporos Rep       Date:  2012-09       Impact factor: 5.096

3.  Loss of BMPR2 leads to high bone mass due to increased osteoblast activity.

Authors:  Jonathan W Lowery; Giuseppe Intini; Laura Gamer; Sutada Lotinun; Valerie S Salazar; Satoshi Ote; Karen Cox; Roland Baron; Vicki Rosen
Journal:  J Cell Sci       Date:  2015-02-06       Impact factor: 5.285

Review 4.  The multiple facets of periostin in bone metabolism.

Authors:  B Merle; P Garnero
Journal:  Osteoporos Int       Date:  2012-02-07       Impact factor: 4.507

5.  Biological functions of miR-29b contribute to positive regulation of osteoblast differentiation.

Authors:  Zhaoyong Li; Mohammad Q Hassan; Mohammed Jafferji; Rami I Aqeilan; Ramiro Garzon; Carlo M Croce; Andre J van Wijnen; Janet L Stein; Gary S Stein; Jane B Lian
Journal:  J Biol Chem       Date:  2009-04-02       Impact factor: 5.157

6.  The skeletal muscle secretome: an emerging player in muscle-bone crosstalk.

Authors:  Mark W Hamrick
Journal:  Bonekey Rep       Date:  2012-04-11

7.  Activin A suppresses osteoblast mineralization capacity by altering extracellular matrix (ECM) composition and impairing matrix vesicle (MV) production.

Authors:  Rodrigo D A M Alves; Marco Eijken; Karel Bezstarosti; Jeroen A A Demmers; Johannes P T M van Leeuwen
Journal:  Mol Cell Proteomics       Date:  2013-06-17       Impact factor: 5.911

Review 8.  Follistatin as potential therapeutic target in prostate cancer.

Authors:  Maria Vittoria Sepporta; Francesca Maria Tumminello; Carla Flandina; Marilena Crescimanno; Marco Giammanco; Maurizio La Guardia; Danila di Majo; Gaetano Leto
Journal:  Target Oncol       Date:  2013-03-01       Impact factor: 4.493

9.  New insights: elevated follicle-stimulating hormone and bone loss during the menopausal transition.

Authors:  Mone Zaidi; Harry C Blair; Jameel Iqbal; Terry F Davies; Ling Ling Zhu; Alberta Zallone; Li Sun
Journal:  Curr Rheumatol Rep       Date:  2009-07       Impact factor: 4.592

10.  MicroRNA in cardiovascular calcification: focus on targets and extracellular vesicle delivery mechanisms.

Authors:  Claudia Goettsch; Joshua D Hutcheson; Elena Aikawa
Journal:  Circ Res       Date:  2013-03-29       Impact factor: 17.367

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.